title: Nilotinib cardiac toxicity: should we still be concerned?
authors.forename: Ehab
authors.initials: E
authors.lastname: Atallah
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006331:Heart Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D006801:Humans; D051379:Mice; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D018579:Patient Selection; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D051381:Rats; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; C498826:nilotinib